{"filing":{"accession_number":"0001829126-26-007294","cik":"0002079364","ticker":null,"company_name":"Veraxa Biotech AG","form":"6-K","filing_date":"2026-07-06","report_date":null,"primary_document":"veraxabiotechag_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2079364/000182912626007294/veraxabiotechag_6k.htm"},"events":[{"id":16210,"run_id":14466,"accession_number":"0001829126-26-007294","anchor_item_number":"EX-99.1","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"Veraxa Biotech AG has scheduled an extraordinary general meeting for 24 July 2026 to seek shareholder approval for three governance and capital structure matters: (1) increase in conditional capital for shareholder options and amendment of Article 3a; (2) increase in capital band and amendment of Article 3d; and (3) increase in the number of Board members from up to seven and amendment of Article 15. These changes would materially affect the company's capitalization structure and board composition.","company_name":"Veraxa Biotech AG","ticker":null,"filing_date":"2026-07-06","form":"6-K","submitted_at":null,"items":[{"id":14250,"accession_number":"0001829126-26-007294","item_number":"EX-99.1","item_title":"veraxabiotechag_ex99-1.htm","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"This exhibit is a notice and voting instruction form for an extraordinary general meeting of Veraxa Biotech AG scheduled for 24 July 2026. The three agenda items are: (1) increase in conditional capital for shareholder options and amendment of Article 3a; (2) increase in capital band and amendment of Article 3d; and (3) increase in the number of Board members from up to seven and amendment of Article 15. These are governance matters involving shareholder approval of capital structure changes and board composition, which would materially affect investor assessment of the company's capitalization and governance structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-07T18:52:11.792301+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":16211,"run_id":14466,"accession_number":"0001829126-26-007294","anchor_item_number":"EX-99.2","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Veraxa Biotech AG announced the initiation of cell line development with ATUM for its lead BiTAC-TCE program, described as a key milestone in translating the therapeutic candidate into a manufacturable product and advancing toward IND/CTA-enabling activities.","company_name":"Veraxa Biotech AG","ticker":null,"filing_date":"2026-07-06","form":"6-K","submitted_at":null,"items":[{"id":14251,"accession_number":"0001829126-26-007294","item_number":"EX-99.2","item_title":"veraxabiotechag_ex99-2.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces VERAXA's initiation of cell line development with ATUM for its lead BiTAC-TCE program, described as \"an important next step\" and \"key milestone in translating a therapeutic candidate into a manufacturable product\" toward IND/CTA-enabling activities. This is a material operational and strategic milestone in advancing the company's lead clinical program, but it does not fit the specific event categories (not an earnings release, M\u0026A activity, executive change, or other named event type). It represents a significant operational development in the drug development pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-07T18:52:11.792301+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":16212,"run_id":14466,"accession_number":"0001829126-26-007294","anchor_item_number":"EX-99.3","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Veraxa Biotech AG disclosed a material strategic and pipeline update, including decisions to focus investment on BiTAC-based programs, monetize non-BiTAC assets, and pursue partnering initiatives, with VXA-102 targeted to be IND/CTA-ready by early 2028.","company_name":"Veraxa Biotech AG","ticker":null,"filing_date":"2026-07-06","form":"6-K","submitted_at":null,"items":[{"id":14252,"accession_number":"0001829126-26-007294","item_number":"EX-99.3","item_title":"veraxabiotechag_ex99-3.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release discloses a material business and pipeline update, including strategic decisions to focus investment on BiTAC-based programs, monetize non-BiTAC assets, and pursue partnering initiatives. The company announces specific development timelines (VXA-102 IND/CTA-ready by early 2028) and describes its current pipeline composition and partnering strategy. While not a discrete M\u0026A transaction, earnings release, or executive change, this operational and strategic update would affect a reasonable investor's assessment of the company's direction and value drivers.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-07T18:52:11.792301+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14250,"accession_number":"0001829126-26-007294","item_number":"EX-99.1","item_title":"veraxabiotechag_ex99-1.htm","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"This exhibit is a notice and voting instruction form for an extraordinary general meeting of Veraxa Biotech AG scheduled for 24 July 2026. The three agenda items are: (1) increase in conditional capital for shareholder options and amendment of Article 3a; (2) increase in capital band and amendment of Article 3d; and (3) increase in the number of Board members from up to seven and amendment of Article 15. These are governance matters involving shareholder approval of capital structure changes and board composition, which would materially affect investor assessment of the company's capitalization and governance structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-07T18:52:11.792301+00:00","company_name":"Veraxa Biotech AG","ticker":null,"filing_date":"2026-07-06"},{"id":14251,"accession_number":"0001829126-26-007294","item_number":"EX-99.2","item_title":"veraxabiotechag_ex99-2.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces VERAXA's initiation of cell line development with ATUM for its lead BiTAC-TCE program, described as \"an important next step\" and \"key milestone in translating a therapeutic candidate into a manufacturable product\" toward IND/CTA-enabling activities. This is a material operational and strategic milestone in advancing the company's lead clinical program, but it does not fit the specific event categories (not an earnings release, M\u0026A activity, executive change, or other named event type). It represents a significant operational development in the drug development pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-07T18:52:11.792301+00:00","company_name":"Veraxa Biotech AG","ticker":null,"filing_date":"2026-07-06"},{"id":14252,"accession_number":"0001829126-26-007294","item_number":"EX-99.3","item_title":"veraxabiotechag_ex99-3.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release discloses a material business and pipeline update, including strategic decisions to focus investment on BiTAC-based programs, monetize non-BiTAC assets, and pursue partnering initiatives. The company announces specific development timelines (VXA-102 IND/CTA-ready by early 2028) and describes its current pipeline composition and partnering strategy. While not a discrete M\u0026A transaction, earnings release, or executive change, this operational and strategic update would affect a reasonable investor's assessment of the company's direction and value drivers.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-07T18:52:11.792301+00:00","company_name":"Veraxa Biotech AG","ticker":null,"filing_date":"2026-07-06"}]}